• Wed. Feb 1st, 2023

Artificial heart maker CARMAT gets regulatory approvals to resume sales – Reuters

ByINVESTOR

Oct 25, 2022

415 views

PARIS, Oct 25 (Reuters) – French medical devices company CARMAT (ALCAR.PA) said it had received the necessary regulatory approvals to resume commercial implants of its Aeson artificial hearts product and would resume sales soon.

“We will be resuming implants very soon and moving forward at a measured pace as we continue building our inventory of implantable prostheses, and ensure all patients are suitably monitored,” Chief Executive Stéphane Piat said in a statement.

Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez

Our Standards: The Thomson Reuters Trust Principles.

3 thoughts on “Artificial heart maker CARMAT gets regulatory approvals to resume sales – Reuters”

Leave a Reply

Your email address will not be published. Required fields are marked *